Cure My Disease

Don't miss your cure!

 Log in / Sign up

Muscle relaxant showdown: which drug keeps drivers steadier?

NCT ID NCT06382662

Symptom relief Sponsor: Primus Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers compare how two muscle relaxants, metaxalone and tizanidine, affect driving ability and thinking in healthy adults. Each participant takes both drugs one at a time after a high-fat meal, then uses a driving simulator to measure lane control. The study aims to see which drug causes less driving impairment, which could help doctors choose safer options for patients who drive.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
metaxalone
What this could lead to
If metaxalone impairs driving less than tizanidine, it could offer a muscle relaxant option that is safer for people who need to drive.
What could go wrong
This is a small pilot study with 20 healthy volunteers, so the results may not apply to patients or real-world driving. Both drugs can cause drowsiness, and the simulator cannot capture every driving risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

20 people

The number who actually took part.

Started

Apr 2024

Finished

Mar 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * equal to or greater than 18 years old * equal to or less than 65 years old * weight at least 120 pounds * medically healthy * able to eat a high fat meal Exclusion Criteria: * medications known to affect sleep-wake cycle * current use of cimetidine * current use of certain anti-depressants * current use of certain antibiotics * positive urine drug test for mind altering medications

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive impairment are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cognitive impairment

Contacts and locations

Locations

  • Sun Valley Arthritis Center

    Peoria, Arizona, 85381, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.